Artemis Program

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

system
By system
May 13, 2026 • 53 views
Original source: GlobeNewswire
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission …

system
system

Article Author

Related Articles
A New Theory of Dark Matter Could Solve Three Cosmic Mysteries
2 days ago
The devil may wear Prada on Earth, but NASA Artemis astronauts will on the moon. Here's why.
2 days ago
Starlink Mobile challengers back proposed telco-led D2D joint venture
2 days ago
Is it time to expand our thinking about dark matter? A new study says yes
3 days ago
Topic Tags
Nasa Artemis Ii Lunar Mission Space Launch System Artemis Iii Orion Spacecraft Blue Origin Spacex Artemis Program Reid Wiseman Deep Space New Glenn Commercial Launch Low Earth Orbit Orion Tiangong Chinese National Space Administration Crewed Spaceflight Pbs Documentary Moon Exploration Ng 3 Rocket Reusability Be 4 Cape Canaveral Vulcan Centaur United Launch Alliance Space Force Solid Rocket Boosters National Security Space Launch Gem 63xlmotor
Stay Updated

Subscribe to our newsletter for the latest news